Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1. (Q34452127)

2 August 2017

title

Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1. (English)

1 reference

metastatic renal cell carcinoma

2 August 2017

main subject

phase III clinical trial

0 references

renal cell carcinoma

1 reference

based on heuristic

inferred from title

1 reference

1

Taiji Tsukamoto

1 reference

2 August 2017

Nobuo Shinohara

2

1 reference

2 August 2017

Norihiko Tsuchiya

3

1 reference

2 August 2017

Yasuo Hamamoto

4

1 reference

2 August 2017

Masayuki Maruoka

5

1 reference

2 August 2017

Hiroyuki Fujimoto

6

1 reference

2 August 2017

Masashi Niwakawa

7

1 reference

2 August 2017

Hirotsugu Uemura

8

1 reference

2 August 2017

Michiyuki Usami

9

1 reference

2 August 2017

Akito Terai

10

1 reference

2 August 2017

Hiro-omi Kanayama

11

1 reference

2 August 2017

Yoshiteru Sumiyoshi

12

1 reference

2 August 2017

Masatoshi Eto

13

1 reference

2 August 2017

Hideyuki Akaza

14

1 reference

2 August 2017

publication date

21 October 2010

1 reference

Japanese Journal of Clinical Oncology

2 August 2017

published in

1 reference

2 August 2017

volume

41

1 reference

2 August 2017

issue

1

1 reference

2 August 2017

page(s)

17-24

1 reference

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

2 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012894

Current algorithms and prognostic factors in the treatment of metastatic renal cell carcinoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012894

Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumors

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012894

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012894

Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012894

mTOR signalling in human cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012894

The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012894

Sorafenib in advanced clear-cell renal-cell carcinoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012894

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012894

Therapeutic targets: MTOR and related pathways

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012894

Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012894

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012894

Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012894

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012894

Prevalence of renal cell carcinoma: a nation-wide survey in Japan, 2002

6 July 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20965941

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1093/JJCO/HYQ166

1 reference

2 August 2017

1 reference

2 August 2017

1 reference